中文Pick up almost any prescription bottle and you will find a wall of tiny print — dosage, warnings, manufacturer. What you will not easily find is the single fact many patients most want to know: where, exactly, was this medicine made? A bipartisan bill now moving through the US Senate wants to change that, and the packaging world should be paying close attention.
The CLEAR LABELS Act — formally the Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act — has taken a concrete step forward. After being presented to the Senate Committee on Health, Education, Labor, and Pensions on 22 July 2026, the committee advanced it on 27 July to the Senate Legislative Calendar under General Orders, positioning it for consideration by the full Senate.
Introduced by Senator Rick Scott (R-FL) on 5 February 2026, the bill would mandate country-of-origin disclosure for both finished pharmaceutical products and their active pharmaceutical ingredients (APIs). It would also require a searchable electronic database containing country-of-origin information for every API used in FDA-approved drugs sold in the United States.
Under the proposal, finished drug products would carry details of the manufacturer, packer or distributor, plus a link, barcode, QR code, or other electronic means to reach that portal. Manufacturers, packers and distributors would have to make the information available both electronically and through package inserts or paper copies on request.
The driver is supply chain visibility — or the lack of it. Many prescription drugs and APIs are manufactured overseas, particularly in China and India, yet current federal labelling rules do not require public disclosure of those origins. That leaves patients, pharmacists and healthcare providers without a clear line of sight into where their medicine comes from. Senator Scott calls the bill “a commonsense approach” to protecting patient safety by requiring clear disclosure of original manufacturers.
The legislation has gathered bipartisan backing, with 12 cosponsors: 11 Republicans and one Democrat, Senator Kirsten Gillibrand of New York. A companion bill (H.R.8269) was introduced in the House by Representative Rich McCormick (R-GA) on 14 April 2026 and currently has two cosponsors.
For the packaging and labelling supply chain, the implications are real. A mandated QR code or barcode on every drug package is a labelling specification change at enormous scale, touching cartons, leaflets and the serialization systems already in place across pharma. Printers and converter partners who serve the pharmaceutical market will feel the ripple.
There is a long road still ahead. With the bill now on the Senate Legislative Calendar, it awaits scheduling for debate and a vote. If it passes the Senate, it must clear the House in identical form before reaching the President. According to GovTrack analysis, only about one in four bills are even reported out of committee — so reaching the Senate floor is already a notable milestone. Any final rules would take effect no earlier than one year after publication, and would apply to drugs manufactured on or after that date.
Whatever the outcome, the momentum is telling. Transparency about where medicines are made has moved from a niche concern to a bipartisan legislative priority. For an industry built on putting the right information on the right package, that is a signal worth reading.
Source: Packaging Digest — “Senate Advances CLEAR LABELS Drug Transparency Act” (18 August 2026)
